---
author: Anthropic
date: '2025-10-20'
guest: ''
layout: post.njk
source: https://www.youtube.com/watch?v=NfoFdsc2ODQ
speaker: Anthropic
tags:
  - drug-discovery
  - clinical-trials
  - ai-strategy
  - pharmaceutical-industry
  - change-management
title: 艾伯维如何利用AI加速药物发现与临床开发
summary: 艾伯维（AbbVie）的AI战略与合作副总裁Sarah Nam分享了公司如何将AI技术融入药物发现和临床开发的各个环节，以加速创新并提升患者影响。她详细介绍了AI在优化药物设计、精准医疗、临床试验设计与执行以及自动化文档撰写等方面的应用，并强调了变革管理、人才培养和早期成功示范在推动企业级AI转型中的关键作用。文章还探讨了评估AI技术合作伙伴的标准以及未来AI在制药领域的发展前景。
insight: ''
draft: true
series: ''
category: business
area: tech-insights
project:
  - ai-impact-analysis
  - systems-thinking
people:
  - Ivy Weng
  - Sarah Nam
companies_orgs:
  - AbbVie
  - Anthropic
products_models:
  - Claude
  - GenAIsys
  - GAIA
media_books: []
status: evergreen
---
### AI在制药行业的变革性力量

Sarah Nam: 制药行业中，没有任何其他技术变革能够像人工智能一样，彻底重塑每一个职能。我们相信，这确实是一个百年一遇的机会，能够加速我们的进步，并为患者带来更大的影响。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">There is no other technological shift that has an ability to reimagine every single function within the pharmaceutical industry. And we believe that this is truly a once in a generation opportunity for us to accelerate our progress and our impact for patients.</p>
</details>

Ivy Weng: 大家好，我是Ivy Weng，我在Anthropic的**医疗健康与生命科学市场推广团队**（Healthcare & Life Sciences Go-to-Market team）工作。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Hi everyone. I'm Ivy Weng. I'm on the Healthcare & Life Sciences Go-to-Market team here at Anthropic.</p>
</details>

Sarah Nam: 大家好，我叫Sarah Nam，我是艾伯维（**AbbVie**：一家全球生物制药公司）**AI战略与合作**（AI Strategy and Partnerships）部门的副总裁。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Hi everyone. My name is Sarah Nam, and I'm the Vice President of AI Strategy and Partnerships at AbbVie.</p>
</details>

Ivy Weng: 非常感谢您加入我们，Sarah。也许您可以先介绍一下您在艾伯维的角色和职责范围。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Thank you so much for joining us, Sarah. Maybe you could start by telling us a little bit about your role at AbbVie and the remit.</p>
</details>

### 艾伯维的AI战略与合作

Sarah Nam: 是的，我目前负责开发一个名为**AI战略与合作**（AI Strategy and Partnerships）的新职能部门，我的团队职责主要有两方面。首先是领导我们的**企业级AI战略**（enterprise AI strategy），包括定义我们在业务中与AI相关的战略重点，以及许多**跨领域赋能因素**（cross-cutting enablers），例如从**技术架构**（tech architecture）到**数据现代化**（data modernization）再到**变革管理**（change management）等，这些都使我们能够实现这一目标。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Yes, I'm currently serving in developing a new function called AI Strategy and Partnerships, and the remit of my team is really twofold. The first is to lead our enterprise AI strategy in terms of defining what are our strategic priorities related to AI across our business, as well as many of the cross-cutting enablers that allow us to make that happen from the tech architecture to the data modernization to change management among others.</p>
</details>

Sarah Nam: 我的第二个职责是关于艾伯维的**业务拓展**（business development）和**外部创新**（external innovation）。我们希望成立一个全新的团队，专注于与AI相关的业务拓展。这就是我在艾伯维所扮演的角色。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The second hat that I play is around our business development and external innovation at AbbVie. We wanted to stand up an entirely new team that would focus on business development related to AI. And so that's a little bit about the role that I play at AbbVie.</p>
</details>

### AI在生物制药生命周期中的应用

Ivy Weng: 我们认为艾伯维是生命科学领域部署AI的领导者，如果您能描绘一下AI是如何在整个**生物制药生命周期**（biopharma lifecycle）中部署的，那将非常棒。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We see AbbVie as a leader in deploying AI in life sciences, and it would be great if you could paint a picture around how AI has been deployed across the biopharma lifecycle.</p>
</details>

Sarah Nam: 没有其他技术变革能够像人工智能一样，彻底重塑制药行业中的每一个职能。我们相信，这确实是一个百年一遇的机会，能够加速我们的进步，并为患者带来更大的影响。在艾伯维，我们正在采取一种**基于价值链的方法**（value chain-based approach）来实施这一战略，并能够真正识别艾伯维内部每个职能部门的AI核心优先事项，并针对这些优先事项部署AI用例。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">There is no other technological shift that has an ability to reimagine every single function within the pharmaceutical industry. And we believe that this is truly a once in a generation opportunity for us to accelerate our progress and our impact for patients. And we're taking a very value chain-based approach to how we do this at AbbVie and really being able to identify what are the core priorities for AI across each function within AbbVie and being able to deploy AI use cases against them.</p>
</details>

Sarah Nam: 接下来我将向您介绍一些核心职能以及我们优先考虑AI的领域。在**药物发现**（drug discovery）方面，我们深受启发，希望通过AI更有效地理解**人类生物学**（human biology），并能够大规模地**设计、制造、测试和验证**（design, make, test, and validate）新疗法。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so I'll walk you through some of the core functions and where we're prioritizing AI. Within drug discovery, we're deeply inspired by the ways in which we can better understand human biology and be able to design, make, test, and validate new therapies at scale much more effectively through AI.</p>
</details>

Sarah Nam: 我们还非常关注药物设计中的**多参数优化**（multiparametric optimization），以更有效地提升**人体疗效**（human efficacy）、**安全性**（safety）和**药代动力学**（pharmacokinetics：药物在体内的吸收、分布、代谢和排泄过程），无论是在**小分子药物**（small molecule）还是**生物制剂领域**（biologic space）。此外，我们投入大量时间研究如何通过整合**临床数据**（clinical data）、**基因组数据**（genomic data）和各种**多模态数据**（multimodal data：结合多种数据类型，如图像、文本、基因组等），更有效地大规模推动**适应症拓展**（indication expansion）和**联合用药研究**（combination studies）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">We're also focused a lot on multiparametric optimization of human efficacy, safety, and pharmacokinetics when it comes to designing drugs, both in the small molecule and biologic space a lot more effectively. And in addition, we're spending a lot of time around how we do indication expansion in combination studies by really pulling together clinical data, genomic data, and multimodal data of all kinds, to be able to drive that more effectively at scale.</p>
</details>

Sarah Nam: 最后，我们还在**精准医疗**（precision medicine）方面投入了大量时间，首先从**数字病理学**（digital pathology：利用数字图像技术分析病理切片）开始，但真正扩展了我们如何以更精确的方式为患者提供药物。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And lastly, we're also spending a lot of time around precision medicine, starting first with digital pathology, but really expanding upon the ways in which we could deliver medicines in a much more precise way for our patients.</p>
</details>

Sarah Nam: 此外，当我们考虑**临床开发**（clinical development）时，在**临床试验**（clinical trials）的设计和执行方面，我们有太多可以做的事情。在临床试验设计方面，我们正在投入时间研究如何利用AI更好地指导试验的**入组/排除标准**（inclusion exclusion criteria），以及如何考虑**自适应临床试验设计**（adaptive clinical trial designs：允许在试验进行中根据数据调整方案），并能够真正识别出对我们的药物更可能产生反应的**患者亚群**（patient subpopulations），尤其对于**异质性疾病**（heterogeneous diseases）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">In addition, as we think about clinical development, there is so much that we could do as it relates to how we design and conduct clinical trials. On the design of clinical trials, we're spending time around how we can leverage AI to better inform our inclusion exclusion criteria for trials to how we think about adaptive clinical trial designs and really being able to identify patient subpopulations that are more likely to respond to our drugs for heterogeneous diseases.</p>
</details>

Sarah Nam: 然后，当我们考虑运行临床试验时，在**自动化流程**（automate processes）方面也有很多可以做的事情，以及**文档撰写**（authoring documents），这些文档与**文件提交**（document submission）、**监管要求**（regulatory requirements）等相关。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then as we think about running the clinical trials, there's also so much that we could do in terms of being able to automate a lot of the processes related to clinical trials, as well as authoring documents that are related to document submission, regulatory requirements among others in that space.</p>
</details>

Sarah Nam: 最后，我们在临床开发领域的**数据监测**（data surveillance）方面也做了很多工作，我们可以真正利用AI来查看不同项目中传入的临床数据类型，并进行相应的调整。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then lastly, there's also a lot that we're doing around data surveillance within the clinical development space, and that we could really be able to leverage AI to look at the types of clinical data that's coming in for our different programs and be able to adjust accordingly.</p>
</details>

### 具体的AI用例：GenAIsys和GAIA

Ivy Weng: 您所描述的正是我们正在经历的**拐点**（inflection point），我们正在从加速发展转向**AI转型**（AI transformation）。听起来您正在描述这在**临床工作流程**（clinical workflows）、**商业工作流程**（commercial workflows）和**监管工作流程**（regulatory workflows）中的应用。您能否深入探讨一两个例子并向我们详细说明？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I mean, what you're describing is exactly the inflection point that we are experiencing where we're moving from acceleration to AI transformation. And it sounds like you're describing this across clinical workflows, commercial workflows, regulatory workflows. Are you able to dive into maybe one or two examples and walk us through that?</p>
</details>

Sarah Nam: 我们合作的几个领域包括**GenAIsys**，它是一个我们开发的工具，利用**生成式AI**（generative AI）来整合许多不同的**销售团队相关工具**（sales force-related tools），帮助我们的销售团队在**拜访计划**（call planning）中更有效率。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">A few areas that we've worked together on include, one is around GenAIsys, and GenAIsys is a tool that we've developed that leverages generative AI to really pull forward a lot of the different sales force-related tools that are helping our sales force be much more effective in their call planning.</p>
</details>

Sarah Nam: 这是一项巨大的努力，使艾伯维的**销售代表**（sales reps）在工作中更有效率和效益。早期结果表明，通过像GenAIsys这样的工具，我们的销售团队在效率和效益方面取得了非常显著的提升。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And so this has been a tremendous effort that has allowed our sales reps across AbbVie to be much more effective and efficient in what they do. And early results are showing that there's been very significant improvements in terms of efficiency and effectiveness of our sales force that are enabled by a tool like GenAIsys.</p>
</details>

Sarah Nam: 此外，我们还合作开发了**GAIA**，这是一个临床开发文档撰写工具，我们利用**大型语言模型**（large language models）来自动化许多研究文档的撰写，首先从**NDA**（New Drug Application：新药申请）和**PSUR**（Periodic Safety Update Report：定期安全性更新报告）文档开始，但最终将扩展到数千种不同的文档类型。这使得艾伯维在撰写这些文档方面节省了大约40%到60%的时间。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">In addition, we've partnered on GAIA, which is a clinical development document authoring tool whereby we're leveraging large language models to essentially automate the writing and authoring of a lot of our study documents, starting first with NDA and PSUR documents, but really to thousands of different document types. And this has led to roughly 40 to 60% efficiencies in terms of time saving and writing some of these documents across AbbVie.</p>
</details>

### AI转型中的变革管理

Ivy Weng: 我认为Anthropic以及我们正在构建的模型之所以如此令人兴奋，部分原因在于我们将其视为驱动所有这些适用于**生命科学公司**（life sciences firms）不同用例的**驱动引擎**（engine powering）。我们经常思考的一个问题是，我们看到**编码被采纳**（coding being adopted）并真正**普及**（proliferated）。我们认为编码的价值也可以转移或在其他行业中体验。但我认为，从根本上讲，当我们与大型企业合作时，当涉及到大量的**变革管理**（change management）时，会存在一些非常**实际的问题**（pragmatic issues）。您认为这在艾伯维是如何体现的？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think part of what makes Anthropic and the models that we're building so exciting is that we see this as the engine powering all of these different use cases that are applicable to life sciences firms. Something that we think about a lot is, you know, we see coding being adopted and has proliferated, really. And you know, we think that value from coding can be transferred or you know, can be experienced in other industries, too. But I think fundamentally there are some very pragmatic issues or problems when we're working with larger enterprises when there's a lot of change management involved. How do you see that playing out at AbbVie?</p>
</details>

Sarah Nam: 这不仅是一个技术挑战，更重要的是要触动人们的心灵和思想，以及所需的流程管理。因此，我们发现，在大型企业中真正推动AI转型时，关注人员和流程与许多技术决策同等重要。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">It's not only a technology challenge, but it's also really moving people's hearts and minds and also the process management that's needed. And so we have found that focusing on people and processes are equally as important as many of the technology decisions and truly driving an AI transformation at a large enterprise.</p>
</details>

Sarah Nam: 艾伯维在变革管理方面的一些重点包括**技能提升**（upskilling），例如在组织各个层面开展**AI培训项目**（AI training programs），从刚刚开始学习AI的人员，到代表我们许多职能部门开发AI解决方案的更**熟练从业者**（proficient practitioners）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Some of the ways that we've been focusing on change management in AbbVie include upskilling in terms of doing AI training programs at all levels across the organization from those that are just starting on their journey to learn AI all the way to the more proficient practitioners that are developing the AI solutions on behalf of many of our functions.</p>
</details>

Sarah Nam: 此外，我们专注于展示**早期成功**（early wins），通过关注少数几个能够产生**近期投资回报率**（near-term ROI）、**财务回报**（financial returns）并对患者产生影响的用例，这些用例能够真正推动我们业务中每个职能部门的**关键指标**（golden metrics），这对于变革管理至关重要。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And in addition, we're focused on demonstrating early wins that by being able to focus on a few use cases that generate near-term ROI, financial returns, impact for our patients that really move the needle on true golden metrics in our business, in each of our functions has been really critical to that change management.</p>
</details>

Sarah Nam: 最后，我们一直在**赋能倡导者**（empowering champions），在每个职能部门中都成立了小型AI团队，这些团队作为真正的倡导者，在各自领域推动AI转型。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then lastly, it's been really empowering champions within each of our functions that we are standing up small AI teams across each of the functions that serve as true champions that bring forward a lot of the AI transformation in their respective domains.</p>
</details>

### 评估AI技术合作伙伴的标准

Ivy Weng: 当您的团队评估或寻找新的AI技术合作伙伴时，您会使用哪些标准？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">When your teams are evaluating or looking at new AI technology partners, what are some of the criteria that you use?</p>
</details>

Sarah Nam: 我们的组织最近开发了一个详细的**尽职调查框架**（diligence framework），用于评估AI驱动的合作关系，我们关注四个关键支柱。第一个是关于**战略契合度**（strategic fit）。实际的合作关系如何符合我们组织的战略目标？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Our organization recently developed a detailed diligence framework for how we would evaluate AI-driven partnerships, and there's four key pillars that we focus on. One is really around the strategic fit. How does the actual partnership fit in terms of the strategic objectives of the organization that we have?</p>
</details>

Sarah Nam: 第二个是关于**技术基础**（technical foundation），即合作伙伴提供的AI产品有多么**差异化**（differentiated AI offering）？实际的**数据生成能力**（data generation capabilities）是什么？他们提供的模型在**比较差异化**（comparative differentiation）方面如何？并能够以非常系统的方式进行尽职调查。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The second is really around the technical foundation in terms of how differentiated is the AI offering that the partner is providing? What is the actual data generation capabilities, what's the comparative differentiation in the models that they're providing? And really being able to diligence that in a very systematic way.</p>
</details>

Sarah Nam: 我们关注的第三个支柱是**管理团队**（management team）。通常，特别是对于AI驱动的药物发现合作，我们寻找的是那些真正了解我们领域以及我们正在寻找的深厚AI和机器学习经验的团队。管理团队具备这种**双语能力**（bilingualism：指既懂业务又懂技术）对我们来说至关重要。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The third pillar that we look at is really around the management team. And so typically, especially with AI-driven drug discovery partnerships, we're looking at ones that truly understand our domain as well as the deep AI and ML experience that we're looking for. And having that kind of bilingualism in terms of the management team is really critical for us.</p>
</details>

Sarah Nam: 我们关注的最后一个支柱是**外部验证**（external validation）。因此，通过**案例研究**（case studies）来**基准测试实际影响**（benchmarking real impact）对我们来说至关重要，主要是在我们如何评估AI驱动的药物发现合作伙伴方面。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And then the last pillar that we look at is really around external validation. And so looking towards benchmarking real impact in terms of case studies has been really critical for us, primarily around how we evaluate AI-driven drug discovery partners.</p>
</details>

### 给其他制药高管的建议

Ivy Weng: 我很喜欢这个框架。如果您要与其他**制药高管**（pharma exec）交流，您会告诉他们关于他们的**AI转型之旅**（AI transformation journey）什么？您有什么建议给他们吗？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I love that framework. If you were to speak with another pharma exec, what would you tell them about, you know, going on their own AI transformation journey? Any advice you have for them?</p>
</details>

Sarah Nam: 我认为我的建议是，从小处着手，开始识别几个可以作为**快速成功**（quick wins）和早期影响示范的领域。一旦这些被证明能够带来投资回报，在某种程度上就可以**自我资助**（self-fund）其余的AI计划，但这些早期成功将真正推动整个组织的巨大转型。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I think my advice would be to start simple, start to identify a few areas that could serve as quick wins and early demonstrations of impact. And once those are demonstrated in the ROI, in some ways can then self-fund the rest of the AI initiatives, but those early wins will really enable tremendous amount of transformation across the organization.</p>
</details>

Ivy Weng: 这与我们产生了强烈共鸣。我认为我们经常思考的一点是，**不作为的风险**（risk of inaction）太大了，我认为很多公司都不愿意承担这种风险。鉴于这个领域的所有创新，您对未来三到五年内AI和制药领域最兴奋的是什么？

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">That really resonates with us. I think something that we think about a lot is the risk of inaction is just too great, and that's not something that I think a lot of companies are willing to take. Given all the innovation in this space, what are you most excited about in the next three to five years around AI and pharma?</p>
</details>

### 未来展望：AI在制药领域的激动人心前沿

Sarah Nam: 我非常兴奋AI将以有意义的方式**拓展药物发现的前沿**（push the frontiers of drug discovery）。我非常兴奋的几个领域是：首先，**生成模型**（generative models）可以推动前沿，不仅能够**预测分子特性**（predict molecular properties），还能够以非常有意义的方式辅助**从头设计**（de novo design：指不依赖现有结构，从零开始设计新分子）小分子和生物制剂。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">I'm very excited about the ways in which AI will push the frontiers of drug discovery in a meaningful way. A few areas that I'm very excited about is one, that generative models can push the frontiers in terms of not only being able to predict molecular properties, but also aid in de novo design of small molecules and biologics in a really meaningful way.</p>
</details>

Sarah Nam: 我非常兴奋的第二个领域是能够开发**智能体模型**（agentic models：能够自主感知、推理、规划和行动的AI模型），这些模型可以帮助我们从**基因组学**（genomics：研究生物体基因组的学科）到**蛋白质组学**（proteomics：研究生物体蛋白质的学科），到**转录组学**（transcriptomics：研究生物体转录组的学科），到临床数据，再到**真实世界数据**（real-world data）等**多模态数据集**（multimodal data sets）中**收集并主动推理**（glean and actively reason against），并能够真正**整合这些洞察**（integrate those insights）来解决我们正在研究的**生物学问题**（biological problems）。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">The second area that I'm very excited about is around being able to develop agentic models that can help us glean and actively reason against multimodal data sets from genomics to proteomics, to transcriptomics, to clinical, to real-world data in a meaningful way, and really be able to integrate those insights to address biological problems that we're working on.</p>
</details>

Sarah Nam: 第三个是关于**患者分层**（patient stratification：根据患者特征将其分为不同亚组），这不仅可以帮助我们发现**治疗方法**（therapeutics），还可以帮助我们设计未来的临床试验。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">And the third is around patient stratification, that this could really help us not only in the discovery of therapeutics, but also in how we design our clinical trials going forward as well.</p>
</details>

Ivy Weng: 非常感谢您今天加入我们。很高兴能邀请到您。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Thank you so much for joining us today. It's been wonderful having you.</p>
</details>

Sarah Nam: 非常感谢您，Ivy。

<details>
<summary>View/Hide Original English</summary>
<p class="english-text">Thank you so much, Ivy.</p>
</details>